Fri, February 4, 2022
Thu, February 3, 2022
Wed, February 2, 2022
Tue, February 1, 2022
Mon, January 31, 2022
Sun, January 30, 2022
Fri, January 28, 2022
Thu, January 27, 2022

David Lebovitz Maintained (BPMC) at Hold with Decreased Target to $92 on, Feb 1st, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-92-on-feb-1st-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

David Lebovitz of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Decreased Target from $111 to $92 on, Feb 1st, 2022.

David has made no other calls on BPMC in the last 4 months.



There are 4 other peers that have a rating on BPMC. Out of the 4 peers that are also analyzing BPMC, 0 agree with David's Rating of Hold.



These are the ratings of the 4 analyists that currently disagree with David


  • Bradley Canino of "Stifel" Upgraded from Hold to Strong Buy and Decreased Target to $95 on, Tuesday, January 25th, 2022
  • Andrew Berens of "SVB Leerink" Maintained at Buy with Decreased Target to $120 on, Wednesday, January 12th, 2022
  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $122 on, Monday, January 3rd, 2022
  • Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $133 on, Wednesday, November 10th, 2021

Publication Contributing Sources